Creative Planning’s Rosetta Genomics Ltd. ROSG Stock Holding History

Creative Planning’s Portfolio ROSG Stock Details ROSG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-117	Closed	–	–	5080
2017 Q1	$0	Buy	+117	New	+$630	﹤0.01%	5112
2015 Q2	–	Sell	-417	Closed	-$15K	–	3774
2015 Q1	$15K	Buy	+417	New	+$15.8K	﹤0.01%	2952
2014 Q4	–	Sell	-33	Closed	-$1K	–	4476
2014 Q3	$1K	Hold	33	–	–	﹤0.01%	3928
2014 Q2	$2K	Hold	33	–	–	﹤0.01%	3578
2014 Q1	$2K	Hold	33	–	–	﹤0.01%	3426
2013 Q4	$1K	Hold	33	–	–	﹤0.01%	3264
2013 Q3	$1K	Sell	33 -167	-84%	-$6.78K	﹤0.01%	3155
2013 Q2	$8K	Buy	+200	New	+$8.88K	﹤0.01%	2381

Other funds holding ROSG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HCM

Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Creative Planning's ROSG Position: Q2 2017 in Review

Creative Planning sold out of Rosetta Genomics Ltd. (ROSG) in Q2 2017, closing a stake of 117 shares.

Creative Planning first reported a position in ROSG in Q2 2013 and held it in 8 quarters. The position peaked at $15K in Q1 2015. 6 funds tracked by Wall St. Rank hold ROSG as of Q2 2017.

Creative Planning reported no remaining Rosetta Genomics Ltd. position as of Q2 2017 after selling out during the quarter.
Creative Planning sold 117 Rosetta Genomics Ltd. shares in Q2 2017.
Creative Planning first reported a position in Rosetta Genomics Ltd. in Q2 2013 and held it in 8 quarters.
Creative Planning's Rosetta Genomics Ltd. position peaked at $15K in Q1 2015.
6 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2017.

Based on Creative Planning's 13F filing for Q2 2017, filed 12 Jul 2017.